130 related articles for article (PubMed ID: 19058218)
21. Molecular subtypes of breast cancer are associated with characteristic DNA methylation patterns.
Holm K; Hegardt C; Staaf J; Vallon-Christersson J; Jönsson G; Olsson H; Borg A; Ringnér M
Breast Cancer Res; 2010; 12(3):R36. PubMed ID: 20565864
[TBL] [Abstract][Full Text] [Related]
22. Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization.
Sabatier R; Finetti P; Guille A; Adelaide J; Chaffanet M; Viens P; Birnbaum D; Bertucci F
Mol Cancer; 2014 Oct; 13():228. PubMed ID: 25277734
[TBL] [Abstract][Full Text] [Related]
23. Raf kinase inhibitory protein role in the molecular subtyping of breast cancer.
Al-Mulla F; Marafie M; Zea Tan T; Paul Thiery J
J Cell Biochem; 2014 Mar; 115(3):488-97. PubMed ID: 24123286
[TBL] [Abstract][Full Text] [Related]
24. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
25. Identification of cell-of-origin breast tumor subtypes in inflammatory breast cancer by gene expression profiling.
Van Laere SJ; Van den Eynden GG; Van der Auwera I; Vandenberghe M; van Dam P; Van Marck EA; van Golen KL; Vermeulen PB; Dirix LY
Breast Cancer Res Treat; 2006 Feb; 95(3):243-55. PubMed ID: 16261404
[TBL] [Abstract][Full Text] [Related]
26. Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.
Kolacinska A; Chalubinska J; Zawlik I; Szymanska B; Borowska-Garganisz E; Nowik M; Fendler W; Kubiak R; Pawlowska Z; Morawiec Z; Szemraj J
Neoplasma; 2012; 59(4):424-32. PubMed ID: 22489698
[TBL] [Abstract][Full Text] [Related]
27. Subtypes of familial breast tumours revealed by expression and copy number profiling.
Waddell N; Arnold J; Cocciardi S; da Silva L; Marsh A; Riley J; Johnstone CN; Orloff M; Assie G; Eng C; Reid L; Keith P; Yan M; Fox S; Devilee P; Godwin AK; Hogervorst FB; Couch F; ; Grimmond S; Flanagan JM; Khanna K; Simpson PT; Lakhani SR; Chenevix-Trench G
Breast Cancer Res Treat; 2010 Oct; 123(3):661-77. PubMed ID: 19960244
[TBL] [Abstract][Full Text] [Related]
28. Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance.
Karn T; Ruckhäberle E; Hanker L; Müller V; Schmidt M; Solbach C; Gätje R; Gehrmann M; Holtrich U; Kaufmann M; Rody A
Breast Cancer Res Treat; 2011 Nov; 130(2):409-20. PubMed ID: 21203899
[TBL] [Abstract][Full Text] [Related]
29. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
Kao J; Salari K; Bocanegra M; Choi YL; Girard L; Gandhi J; Kwei KA; Hernandez-Boussard T; Wang P; Gazdar AF; Minna JD; Pollack JR
PLoS One; 2009 Jul; 4(7):e6146. PubMed ID: 19582160
[TBL] [Abstract][Full Text] [Related]
30. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers.
Natrajan R; Weigelt B; Mackay A; Geyer FC; Grigoriadis A; Tan DS; Jones C; Lord CJ; Vatcheva R; Rodriguez-Pinilla SM; Palacios J; Ashworth A; Reis-Filho JS
Breast Cancer Res Treat; 2010 Jun; 121(3):575-89. PubMed ID: 19688261
[TBL] [Abstract][Full Text] [Related]
31. Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.
Staaf J; Ringnér M; Vallon-Christersson J; Jönsson G; Bendahl PO; Holm K; Arason A; Gunnarsson H; Hegardt C; Agnarsson BA; Luts L; Grabau D; Fernö M; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
J Clin Oncol; 2010 Apr; 28(11):1813-20. PubMed ID: 20231686
[TBL] [Abstract][Full Text] [Related]
32. Breast cancer molecular subtypes respond differently to preoperative chemotherapy.
Rouzier R; Perou CM; Symmans WF; Ibrahim N; Cristofanilli M; Anderson K; Hess KR; Stec J; Ayers M; Wagner P; Morandi P; Fan C; Rabiul I; Ross JS; Hortobagyi GN; Pusztai L
Clin Cancer Res; 2005 Aug; 11(16):5678-85. PubMed ID: 16115903
[TBL] [Abstract][Full Text] [Related]
33. Molecular classification of estrogen receptor-positive/luminal breast cancers.
Geyer FC; Rodrigues DN; Weigelt B; Reis-Filho JS
Adv Anat Pathol; 2012 Jan; 19(1):39-53. PubMed ID: 22156833
[TBL] [Abstract][Full Text] [Related]
34. [Molecular classification of breast cancer].
Zepeda-Castilla EJ; Recinos-Money E; Cuéllar-Hubbe M; Robles-Vidal CD; Maafs-Molina E
Cir Cir; 2008; 76(1):87-93. PubMed ID: 18492427
[TBL] [Abstract][Full Text] [Related]
35. Identification and validation of an ERBB2 gene expression signature in breast cancers.
Bertucci F; Borie N; Ginestier C; Groulet A; Charafe-Jauffret E; Adélaïde J; Geneix J; Bachelart L; Finetti P; Koki A; Hermitte F; Hassoun J; Debono S; Viens P; Fert V; Jacquemier J; Birnbaum D
Oncogene; 2004 Apr; 23(14):2564-75. PubMed ID: 14743203
[TBL] [Abstract][Full Text] [Related]
36. Distinct genomic aberration patterns are found in familial breast cancer associated with different immunohistochemical subtypes.
Melchor L; Honrado E; García MJ; Alvarez S; Palacios J; Osorio A; Nathanson KL; Benítez J
Oncogene; 2008 May; 27(22):3165-75. PubMed ID: 18071313
[TBL] [Abstract][Full Text] [Related]
37. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
[TBL] [Abstract][Full Text] [Related]
38. Genetic alterations and oncogenic pathways associated with breast cancer subtypes.
Hu X; Stern HM; Ge L; O'Brien C; Haydu L; Honchell CD; Haverty PM; Peters BA; Wu TD; Amler LC; Chant J; Stokoe D; Lackner MR; Cavet G
Mol Cancer Res; 2009 Apr; 7(4):511-22. PubMed ID: 19372580
[TBL] [Abstract][Full Text] [Related]
39. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
[TBL] [Abstract][Full Text] [Related]
40. Cancer stem cell markers are associated with adverse biomarker profiles and molecular subtypes of breast cancer.
Tsang JY; Huang YH; Luo MH; Ni YB; Chan SK; Lui PC; Yu AM; Tan PH; Tse GM
Breast Cancer Res Treat; 2012 Nov; 136(2):407-17. PubMed ID: 23053657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
